The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Persistence of Viremia and the Importance of Long–Term Follow–Up After Acute Hepatitis C Infection
Open accessAbstract
The purpose of this investigation was to prospectively characterize acute hepatitis C virus (HCV) infections and to evaluate the hypothesis that the outcome is affected by identifiable clinical or viral factors. One hundred forty–two people with a history of illicit drug use who were HCV antibody-negative in 1988 were followed semiannually through 1996. HCV seroconversion (second generation enzyme immunoassay and recombinant immunoblot assay) was recognized in 43 (30%) of the participants, who were followed up for a median of 72 months. HCV RNA was detected and quantified by polymerase chain reaction in a median of 10 specimens per participant and showed two distinct patterns of viremia: viral clearance was noted in 6 (14%) of the participants, and viral persistence was observed in 37 (86%) of the participants. Subjects with viral clearance were more likely to be white (P = .004), have jaundice (P = .03), and have lower peak viral titer (P = .003). However, the outcome for a given person could not be predicted by clinical features, RNA level, or HCV subtype (as ascertained by analysis of core–E1 complementary DNA sequence). No acute infections were recognized by health care providers. At the time of seroconversion, HCV RNA was detectable in 81% of participants, and recombinant immunoblot assay (RIBA) was positive in 85% of participants. We conclude that approximately 85% of people with acute hepatitis C develop persistent viremia. However, acute infections are uncommonly recognized clinically, underscoring the importance of screening individuals at risk. Long–term follow–up, but no single laboratory test, is necessary to ascertain the outcome and in some cases make the diagnosis of acute HCV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PHYLIP-Phylogeny inference package (Version 3.2)
Felsenstein, J. (1989) · Cladistics · Cited by 17,682
The Natural History of Community-Acquired Hepatitis C in the United States
Alter, M. J., Margolis, H. S., Krawczynski, K., Judson, F. N., Mares, A., Alexander, W. J., Hu, P. Y., Miller, J. K., Gerber, M. A., Sampliner, R. E., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272702 · Cited by 1,592
Alter, M. J. (1997) · Hepatology · doi:10.1002/hep.510260711 · Cited by 1,075
Genetic Heterogeneity of Hepatitis C Virus: Quasispecies and Genotypes
Bukh, J., Miller, R., & Purcell, R. (1995) · Seminars in Liver Disease · doi:10.1055/s-2007-1007262 · Cited by 833
McMahon, B. J., Alward, W. L. M., Hall, D. B., Heyward, W. L., Bender, T. R., Francis, D. P., & Maynard, J. E. (1985) · Journal of Infectious Diseases · doi:10.1093/infdis/151.4.599 · Cited by 832
Hepatitis C: the clinical spectrum of disease.
Hoofnagle, J. H. (1997) · Hepatology · doi:10.1002/hep.510260703 · Cited by 765
Missale, G., Bertoni, R., Lamonaca, V, Valli, A., Massari, M., Mori, C., Rumi, M. G., Houghton, M., Fiaccadori, F., & Ferrari, C. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118842 · Cited by 658
A long-term study of hepatitis C virus replication in non-A, non-B hepatitis.
Farci, P., Alter, H. J., Wong, D., Miller, R. H., Shih, J. W., Jett, B., & Purcell, R. H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107113250205 · Cited by 571
(1997) · Hepatology · doi:10.1002/hep.510260701 · Cited by 569
Marcellin, P., Boyer, N., Gervais, A., Martinot, M., Pouteau, M., Castelnau, C., Kilani, A., Areias, J., Auperin, A., Benhamou, J. P., et al. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-10-199711150-00003 · Cited by 559
Cited by
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,973
Self-citationGenetic variation in IL28B and spontaneous clearance of hepatitis C virus
Thomas, D. L., Thio, C. L., Martin, M. P., Qi, Y., Ge, D., O’hUigin, C., Kidd, J., Kidd, K., Khakoo, S. I., Alexander, G., et al. (2009) · Nature · doi:10.1038/nature08463 · Cited by 2,150
Self-citationDiagnosis, management, and treatment of hepatitis C†
Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004) · Hepatology · doi:10.1002/hep.20119 · Cited by 1,709
Self-citationNatural history of chronic hepatitis C
Seeff, L. B. (2002) · Hepatology · doi:10.1053/jhep.2002.36806 · Cited by 1,424
Panel, A. H. G. (2015) · Hepatology · doi:10.1002/hep.27950 · Cited by 1,382
Course and outcome of hepatitis C
Hoofnagle, J. H. (2002) · Hepatology · doi:10.1002/hep.1840360704 · Cited by 1,084
The Natural History of Hepatitis C Virus Infection: Host, Viral, and Environmental Factors
Thomas, D. L., Astemborski, J., Rai, R. M., Anania, F. A., Schaeffer, M., Galai, N., Nolt, K., Nelson, K. E., Strathdee, S. A., Johnson, L., et al. (2000) · JAMA · doi:10.1001/jama.284.4.450 · Cited by 1,073
Self-citationGhany, M. G., Morgan, T. R., & Panel, A. H. C. G. (2020) · Hepatology · doi:10.1002/hep.31060 · Cited by 955
Micallef, J. M., Kaldor, J. M., & Dore, G. J. (2006) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2005.00651.x · Cited by 871
The Natural History of Hepatitis C Virus (HCV) Infection
Chen, S. L., & Morgan, T. R. (2006) · International Journal of Medical Sciences · doi:10.7150/ijms.3.47 · Cited by 860
Alter, H. J., & Seeff, L. B. (2000) · Seminars in Liver Disease · doi:10.1055/s-2000-9505 · Cited by 736
Estimating progression to cirrhosis in chronic hepatitis C virus infection
Freeman, A. J., Dore, G. J., Law, M. G., Thorpe, M., Von Overbeck, J., Lloyd, A. R., Marinos, G., & Kaldor, J. M. (2001) · Hepatology · doi:10.1053/jhep.2001.27831 · Cited by 620
Diagnosis and Monitoring of Hepatic Injury. I. Performance Characteristics of Laboratory Tests
Dufour, D. R., Lott, J. A., Nolte, F. S., Gretch, D. R., Koff, R. S., & Seeff, L. B. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.12.2027 · Cited by 571
Chronic hepatitis C virus (HCV) disease burden and cost in the United States
Razavi, H., ElKhoury, A. C., Elbasha, E., Estes, C., Pasini, K., Poynard, T., & Kumar, R. (2013) · Hepatology · doi:10.1002/hep.26218 · Cited by 474
Razavi, H., Waked, I., Sarrazin, C., Myers, R. P., Idilman, R., Calinas, F., Vogel, W., Mendes Correa, M. C., Hézode, C., Lázaro, P., et al. (2014) · Journal of Viral Hepatitis · doi:10.1111/jvh.12248 · Cited by 477
Protection against persistence of hepatitis C
Mehta, S. H., Cox, A., Hoover, D. R., Wang, X.-H., Mao, Q., Ray, S., Strathdee, S. A., Vlahov, D., & Thomas, D. L. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08435-0 · Cited by 440
Self-citationDufour, D. R., Lott, J. A., Nolte, F. S., Gretch, D. R., Koff, R. S., & Seeff, L. B. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.12.2050 · Cited by 439
Alberti, A., & Benvegnù, L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00008-4 · Cited by 438
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
Cornberg, M., Razavi, H. A., Alberti, A., Bernasconi, E., Buti, M., Cooper, C., Dalgard, O., Dillion, J. F., Flisiak, R., Forns, X., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02539.x · Cited by 411
Hepatitis C in the HIV-Infected Person
Sulkowski, M. S., & Thomas, D. L. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-3-200302040-00012 · Cited by 405
Self-citationNatural History of Hepatitis C
Thomas, D. L., & Seeff, L. B. (2005) · Clinics in Liver Disease · doi:10.1016/j.cld.2005.05.003 · Cited by 402
Self-citationden Brinker, M., Wit, F. W. N. M., Wertheim-van Dillen, P. M. E., Jurriaans, S., Weel, J., van Leeuwen, R., Pakker, N. G., Reiss, P., Danner, S. A., Jan Weverling, G., et al. (2000) · AIDS · doi:10.1097/00002030-200012220-00011 · Cited by 390
Limited Uptake of Hepatitis C Treatment Among Injection Drug Users
Mehta, S. H., Genberg, B. L., Astemborski, J., Kavasery, R., Kirk, G. D., Vlahov, D., Strathdee, S. A., & Thomas, D. L. (2008) · Journal of Community Health · doi:10.1007/s10900-007-9083-3 · Cited by 327
Self-citationCellular immune selection with hepatitis C virus persistence in humans
Cox, A. L., Mosbruger, T., Mao, Q., Liu, Z., Wang, X.-H., Yang, H.-C., Sidney, J., Sette, A., Pardoll, D., Thomas, D. L., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050121 · Cited by 306
Self-citationMaheshwari, A., Ray, S., & Thuluvath, P. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61116-2 · Cited by 295
Page, K., Hahn, J. A., Evans, J., Shiboski, S., Lum, P., Delwart, E., Tobler, L., Andrews, W., Avanesyan, L., Cooper, S., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/605947 · Cited by 285
Global control of hepatitis C: where challenge meets opportunity
Thomas, D. L. (2013) · Nature Medicine · doi:10.1038/nm.3184 · Cited by 280
Self-citationOrland, J. R., Wright, T. L., & Cooper, S. (2001) · Hepatology · doi:10.1053/jhep.2001.22112 · Cited by 196
Goodgame, B., Shaheen, N. J., Galanko, J., & El-Serag, H. B. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07678.x · Cited by 72
“in the community-acquired study (34) with a mean age of”
BackgroundHepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy
HALLINAN, R., BYRNE, A., AMIN, J., & DORE, G. J. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.03882.x · Cited by 56
Protease inhibitor therapy for hepatitis C virus-infection
de Leuw, P., & Stephan, C. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1454428 · Cited by 51
. FIB-4 index is associated with hepatocellular carcinoma risk in HIV-infected patients.
Park, L. S., Tate, J. P., Justice, A. C., Lo Re, V., Lim, J. K., Bräu, N., Brown, S. T., Butt, A. A., Gibert, C., Goetz, M. B., et al. (2011) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0582 · Cited by 38
Metadata
- Authors
- Villano, S. A., Vlahov, D., Nelson, K. E., Cohn, S., & Thomas, D. L.
- Venue
- Hepatology
- Published
- 1999-03
- Volume
- 29
- Issue
- 3
- Pages
- 908-914
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2027853774
- Cited by
- 475
- References
- 30
- FWCI
- 14.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.